---
input_text: 'A novel Blind Start study design to investigate vestronidase alfa for
  mucopolysaccharidosis VII, an ultra-rare genetic disease.BACKGROUND: Drug development
  for ultra-rare diseases is challenging because small sample sizes and heterogeneous
  study populations hamper the ability of randomized, placebo-controlled trials with
  a single primary endpoint to demonstrate valid treatment effects. METHODS: To overcome
  these challenges, a novel Blind Start design was utilized in a study of vestronidase
  alfa in mucopolysaccharidosis VII (Sly syndrome), an ultra-rare lysosomal disease,
  that demonstrates the strengths of this approach in a challenging drug-development
  setting. Twelve subjects were randomized to 1 of 4 blinded groups, each crossing
  over to active treatment in a blinded fashion at different timepoints with efficacy
  analysis comparing the last assessment before cross over to after 24 weeks of treatment.
  Study assessments included: Percentage change from baseline in urinary GAG (uGAG);
  a Multi-Domain Responder Index (MDRI) using prespecified minimal important differences
  (6-Minute Walk Test, Forced Vital Capacity, shoulder flexion, visual acuity, and
  Bruininks-Oseretsky Test of Motor Proficiency); fatigue as assessed by the Pediatric
  Quality of Life Inventory  Multidimensional Fatigue Scale; and safety. RESULTS:
  Vestronidase alfa treatment for 24 weeks significantly reduced uGAG excretion (dermatan
  sulfate: 64.8%, p < 0.0001). Most subjects (10/12) had a clinically meaningful improvement
  in at least one MDRI domain with an overall mean change (+-SD) of +0.5 (+-0.8) at
  Treatment Week 24 (p = 0.0527). Exposure-adjusted incidence rates of adverse events
  were similar between groups. CONCLUSIONS: The Blind Start study and MDRI design
  improve statistical power that enhances detection of a positive treatment effect
  in this rare heterogeneous disease and could be utilized for other ultra-rare diseases.'
raw_completion_output: |-
  primary_disease: mucopolysaccharidosis VII

  medical_actions: Blind Start study design;vestronidase alfa treatment;Percentage change from baseline in urinary GAG (uGAG) analysis;Multi-Domain Responder Index (MDRI) analysis;6-Minute Walk Test;Forced Vital Capacity test;shoulder flexion test;visual acuity test;Bruininks-Oseretsky Test of Motor Proficiency;Pediatric Quality of Life Inventory Multidimensional Fatigue Scale assessment;efficacy analysis comparing the last assessment before cross over to after 24 weeks of treatment;safety assessments

  symptoms: increased uGAG excretion;fatigue;dermatan sulfate elevation

  chemicals: vestronidase alfa

  action_annotation_relationships: vestronidase alfa treatment TREATS increased uGAG excretion IN mucopolysaccharidosis VII;vestronidase alfa treatment TREATS dermatan sulfate elevation IN mucopolysaccharidosis VII;Pediatric Quality of Life Inventory Multidimensional Fatigue Scale assessment TREATS fatigue IN mucopolysaccharidosis VII
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  Pediatric Quality of Life Inventory Multidimensional Fatigue Scale assessment TREATS fatigue IN mucopolysaccharidosis VII

  ===

extracted_object:
  primary_disease: MONDO:0009662
  medical_actions:
    - Blind Start study design
    - vestronidase alfa treatment
    - Percentage change from baseline in urinary GAG (uGAG) analysis
    - Multi-Domain Responder Index (MDRI) analysis
    - 6-Minute Walk Test
    - Forced Vital Capacity test
    - shoulder flexion test
    - visual acuity test
    - Bruininks-Oseretsky Test of Motor Proficiency
    - Pediatric Quality of Life Inventory Multidimensional Fatigue Scale assessment
    - efficacy analysis comparing the last assessment before cross over to after 24
      weeks of treatment
    - safety assessments
  symptoms:
    - increased uGAG excretion
    - HP:0012378
    - dermatan sulfate elevation
  chemicals:
    - vestronidase alfa
  action_annotation_relationships:
    - subject: treatment
      predicate: TREATS
      object: increased uGAG excretion
      qualifier: MONDO:0009662
      subject_extension: vestronidase alfa
    - subject: treatment
      predicate: TREATS
      object: dermatan sulfate elevation
      qualifier: MONDO:0009662
      subject_extension: vestronidase alfa
    - subject: Pediatric Quality of Life Inventory Multidimensional Fatigue Scale
        assessment
      predicate: TREATS
      object: HP:0012378
      qualifier: MONDO:0009662
named_entities:
  - id: MONDO:0008891
    label: Brown-Vialetto-Van Laere syndrome
  - id: MAXO:0009004
    label: exome sequencing
  - id: HP:0000407
    label: sensorineural hearing loss
  - id: HP:0002093
    label: respiratory insufficiency
  - id: HP:0010871
    label: sensory ataxia
  - id: HP:0000648
    label: optic atrophy
  - id: CHEBI:17015
    label: riboflavin
  - id: HP:0012469
    label: infantile spasms
  - id: HP:0000789
    label: infertility
  - id: HP:0005268
    label: miscarriage
  - id: CHEBI:16709
    label: pyridoxine
  - id: CHEBI:18405
    label: pyridoxal 5'-phosphate
  - id: CHEBI:27306
    label: vitamin B6
  - id: CHEBI:24041
    label: flavin mononucleotide
  - id: HP:0001250
    label: seizures
  - id: MONDO:0009974
    label: Familial hemophagocytic lymphohistiocytosis
  - id: MAXO:0010030
    label: bone marrow transplantation (BMT)
  - id: CHEBI:28901
    label: busulfan
  - id: CHEBI:4027
    label: cyclophosphamide
  - id: CHEBI:4911
    label: etoposide
  - id: MAXO:0000757
    label: infusion
  - id: CHEBI:41264
    label: busulfan (BU), cyclophosphamide (CP), etoposide (VP16), antithymocyte globulin
      (ATG)
  - id: MAXO:0000750
    label: conditioning regimen
  - id: CHEBI:73896
    label: gene therapy (GT)
  - id: MONDO:0009666
    label: Holocarboxylase synthetase deficiency
  - id: MAXO:0000603
    label: Peritoneal dialysis
  - id: HP:0001942
    label: Metabolic acidosis
  - id: CHEBI:15956
    label: Biotin
  - id: HP:0003256
    label: Coagulopathy
  - id: CHEBI:48669
    label: Tranexamic acid
  - id: CHEBI:48675
    label: antifibrinolytic agents
  - id: MONDO:0020300
    label: Autosomal dominant nocturnal frontal lobe epilepsy
  - id: CHEBI:3387
    label: Carbamazepine
  - id: MONDO:0000903
    label: Myoclonus-dystonia
  - id: MAXO:0000943
    label: Deep Brain Stimulation
  - id: HP:0001252
    label: Hypotonia
  - id: MONDO:0005338
    label: Primary open-angle glaucoma (POAG)
  - id: MAXO:0001082
    label: Trabeculectomy
  - id: MAXO:0000960
    label: Viscocanalostomy
  - id: HP:0007906
    label: Elevated intraocular pressure (IOP)
  - id: HP:0000253
    label: Progressive microcephaly
  - id: HP:0001263
    label: Global developmental delay
  - id: HP:0000365
    label: Hearing loss
  - id: HP:0100785
    label: Insomnia
  - id: CHEBI:15681
    label: GM3
  - id: CHEBI:28892
    label: Ganglioside
  - id: MAXO:0001298
    label: therapies
  - id: MAXO:0000950
    label: Supportive care
  - id: CHEBI:8378
    label: Prednisolone
  - id: MONDO:0015626
    label: Charcot-Marie-Tooth disease (CMT)
  - id: MAXO:0035087
    label: peripheral nerve biopsy
  - id: HP:0011096
    label: demyelination
  - id: HP:0001605
    label: vocal cord paralysis
  - id: MONDO:0007947
    label: Marfan's syndrome
  - id: HP:0001659
    label: aortic regurgitation
  - id: CHEBI:2904
    label: atenolol
  - id: CHEBI:6541
    label: losartan
  - id: MONDO:0004691
    label: Autosomal dominant polycystic kidney disease (ADPKD)
  - id: MAXO:0000004
    label: surgery
  - id: HP:0002586
    label: peritonitis
  - id: HP:0100543
    label: cognitive impairment
  - id: HP:0003546
    label: exercise intolerance
  - id: HP:0001332
    label: dystonia
  - id: HP:0001336
    label: myoclonus
  - id: HP:0001272
    label: cerebellar atrophy
  - id: HP:0002059
    label: cerebral atrophy
  - id: CHEBI:46245
    label: coenzyme Q10 (CoQ10)
  - id: MONDO:0009693
    label: multiple myeloma
  - id: HP:0002720
    label: IgA deficiency
  - id: HP:0006775
    label: multiple myeloma
  - id: MONDO:0011787
    label: Limb-girdle muscular dystrophy type 2I (LGMD2I)
  - id: MONDO:0009662
    label: Sly disease (mucopolysaccharidosis VII)
  - id: HP:0002321
    label: vertigo
  - id: HP:0040268
    label: recurrent infections of the middle ears
  - id: MONDO:0100137
    label: Telomere Diseases
  - id: HP:0005528
    label: Bone marrow failure
  - id: HP:0001394
    label: Liver cirrhosis
  - id: HP:0002206
    label: Pulmonary fibrosis
  - id: HP:0003394
    label: Muscle cramps
  - id: CHEBI:4315
    label: Danazol
  - id: MONDO:0015286
    label: complete DiGeorge syndrome (cDGS)
  - id: MAXO:0010042
    label: Thymus transplantation
  - id: HP:0001973
    label: Autoimmune thrombocytopenia
  - id: HP:0100646
    label: Thyroiditis
  - id: HP:0001875
    label: Neutropenia
  - id: HP:0012378
    label: fatigue
